SII Applies To DCGI To Manufacture Covid Vaccine Sputnik V

NEW DELHI : The Serum Institute of India (SII) has applied to the Drug Controller General of India (DCGI) seeking permission to manufacture Covid-19 vaccine Sputnik V in the country, sources said on Thursday.

The Pune-based firm has also sought approval for test analysis and examination. Russia’s Sputnik V vaccine is currently being manufactured in India by Dr Reddy’s Laboratories.

“The Serum Institute of India (SII) put up an application to the Drugs Controller General of India (DCGI) on Wednesday seeking permission to manufacture the Covid-19 vaccine, Sputnik V, in India,” a source said.

The SII has already told the government that it will be able to manufacture and supply 10 crore Covishield doses in June, while it is also manufacturing the Novavax vaccine, the regulatory clearance for which is awaited from the United States.

The vaccine was given emergency use authorisation (EUA) by the DCGI in April. A consignment of 30 lakh doses of Sputnik V landed in Hyderabad on Tuesday.

  • Related Posts

    Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

    The amendment, notified as the Drugs (Thirteenth Amendment) Rules, 2026, came into force on the date of its publication in the Official Gazette. New Delhi: The Centre has tightened regulations…

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

    The National Pharmaceutical Pricing Authority (NPPA) has said that it is not mandatory for the oncology drug manufacturers who are revising the drug prices as per the recently announced Trade…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

    Centre Mandates Minimum One-Year Shelf Life For Imported Drugs

    For Aakash Healthcare, Community People are Apples of its Eyes

    For Aakash Healthcare, Community People are Apples of its Eyes

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

    Not mandatory to recall stocks released to the market prior to implementation of TMR: NPPA

    Yashoda Medicity: Baby takes a Giant Step in just One Year

    Yashoda Medicity: Baby takes a Giant Step in just One Year

    Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore

    Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore

    GLP-1 injections recalled across the US over sterility concerns

    GLP-1 injections recalled across the US over sterility concerns